The US FDA is taking a measured risk with the approval of Clarus Therapeutics Inc. oral testosterone replacement therapy Jatenzo without any risk management program in a category with a history of high off-label use.
Surprise Approval For Clarus' Oral Testosterone Includes Black Box, No REMS
Jatenzo clears US FDA 15 months after second negative advisory committee review.
